(2R)-2-(环戊基甲基)-丁二酸 4-叔丁酯 | 204637-77-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: (2R)-2-(环戊基甲基)-丁二酸 4-叔丁酯
• 中文别名: (R)2-环戊基甲基-丁二酸-1-叔丁酯；(2R)-2-(环戊基甲基)-丁二酸4-叔丁酯
• 英文名称: (R)-4-(tert-butoxy)-2-(cyclopentylmethyl)-4-oxobutanoic acid
• 英文别名: (2R)-2-(cyclopentylmethyl)-4-[(1,1-dimethylethyl)oxy]-4-oxobutanoic acid；(R)-2-cyclopentyl-methyl-succinic acid 4-tert-butyl ester；(2R)-2-(cyclopentylmethyl)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid
• CAS: 204637-77-4
• 化学式: C₁₄H₂₄O₄
• 分子量: 256.342
• InChiKey: XJAASFPIJJMEQF-LLVKDONJSA-N

物化性质

• 沸点：
  374.2±25.0 °C(Predicted)
• 密度：
  1.066±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  (2R)-2-(环戊基甲基)-丁二酸 4-叔丁酯 在 caesium carbonate 、 lithium diisopropyl amide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 (R)-2-Benzyloxycarbonyl-3-cyclopentylmethyl-succinic acid 4-benzyl ester 1-tert-butyl ester
  参考文献：
  名称：

  Alkylation of succinates: Synthesis of Ro 32–3555

  摘要：

  A short synthesis, based on a succinate acylation-akylation-decarboxylation approach, of the clinical compound Ro 32-3555 is reported. The nature of the selectivity in the mono-alkylation of succinates was examined under varying enolization conditions and in the presence of chaotropic additives. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(97)10179-2
• 作为产物：
  描述：

  3-环戊基丙酸 在 正丁基锂 、 双氧水 、 sodium hexamethyldisilazane 、 三乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 19.0h， 生成 (2R)-2-(环戊基甲基)-丁二酸 4-叔丁酯
  参考文献：
  名称：

  N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model

  摘要：

  Free fatty acid-2 (FFA2) receptor is a G-protein coupled receptor of interest in the development of therapeutics in metabolic and inflammatory disease areas. The discovery and optimization of an N-thiazolylamide carboxylic acid FFA2 agonist scaffold is described. Dual key objectives were to i) evaluate the potential of this scaffold for lead optimization in particular with respect to safety de-risking physicochemical properties, i.e. lipophilicity and aromatic content, and ii) to demonstrate the utility of selected lead analogues from this scaffold in a pertinent in vivo model such as oral glucose tolerance test (OGTT). As such, a concomitant improvement in bioactivity together with lipophilic ligand efficiency (LLE) and fraction sp3 content (Fsp(3)) parameters guided these efforts. Compound 10 was advanced into studies in mice on the basis of its optimized profile vs initial lead 1 (Delta LLE = 0.3, Delta Fsp(3) = 0.24). Although active in OGTT, 10 also displayed similar activity in the FFA2-knockout mice. Given this off-target OGTT effect, we discontinued development of this FFA2 agonist scaffold.

  DOI：

  10.1016/j.bmc.2018.09.015

文献信息

• A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF
  申请人：KANG Jae Hoon

  公开号：US20100168421A1

  公开（公告）日：2010-07-01

  The present invention relates to the novel antibacterial compounds having potent antibacterial activity as inhibitors of peptide deformylase. This invention further relates to pharmaceutically acceptable salts thereof, to processes for their preparation, and to pharmaceutical compositions containing them as an active ingredient.

  本发明涉及具有强效抗菌活性的新型抗菌化合物，作为肽变形酶抑制剂。该发明还涉及其药用盐，其制备方法，以及含有它们作为活性成分的药物组合物。
• 一种金属蛋白酶抑制剂关键中间体的合成方法
  申请人：河南师范大学

  公开号：CN106928096A

  公开（公告）日：2017-07-07

  本发明公开了一种金属蛋白酶抑制剂关键中间体的合成方法，化合物2在碱性条件下与硫酸二甲酯反应得到化合物3；化合物3在三氟醋酸或甲酸作用下选择性水解叔丁基而保留甲酯基得到化合物4；化合物4与O‑(4‑甲氧基苄基)羟胺反应引入羟基被保护的螯合基团异羟肟酸基得到化合物5；化合物5在碱性条件下水解得到目标产物化合物A/B。本发明具有操作简单，方便控制，成本低廉和后处理工艺简单的优点。
• 一类杂环类肽脱甲酰基酶抑制剂及其制备方法和应用
  申请人：中山大学

  公开号：CN109851614B

  公开（公告）日：2023-01-13

  本发明公开了一类杂环类肽脱甲酰基酶抑制剂及其制备方法和应用。所述抑制剂的结构如式(Ⅰ)所示；其中A为五元含氮芳杂环，X、Y、Z各自独立地为C、O、S或N，所述R为单取代基、多取代基或与A成环。本发明所述肽脱甲酰基酶抑制剂结构新颖、活性较佳、毒性小，对于革兰氏阳性菌和革兰氏阴性菌均表现出明显的抑制作用，甚至对于具有多重耐药性的细菌，同样具有很好的抑制作用；同时，所述化合物对于结直肠癌、肺癌和骨肉瘤等肿瘤细胞也具有显著的抑制作用，能够抑制肿瘤细胞的增殖，可制备成为抗菌药物或者抗肿瘤药物进行应用。
• Antibacterial agents
  申请人：Pratt Lisa Marie

  公开号：US06846825B1

  公开（公告）日：2005-01-25

  Compounds of formula (II) are antibacterial agents wherein Q represents a radical of the formula: —N(OH)CH(═O) or the formula: —C(═O)NH(OH); R 1 represents hydrogen, C 1 -C 6 alkyl or C 1 -C 6 alkyl substituted by one or more halogen atoms, or, except when Q is a radical of the formula: —N(OH)CH(═O), a hydroxy, C 1 -C 6 alkoxy, C 1 -C 4 alkenyloxy, amino, C 1 -C 4 alkylamino, or di-(C 1 -C 6 alkyl)amino group; R 2 represents a substituted or unsubstituted C 1 -C 6 alkyl, cycloalkyl(C 1 -C 6 alkyl)- or aryl(C 1 -C 6 alkyl)-group; and A represents a group of formula (IIA), or (IIB) wherein R 4 represents the side chain of a natural or non-natural alpha amino acid, and R 5 and R 6 when taken together with the nitrogen atom to which they are attached form a saturated heterocyclic first ring of 5 to 7 atoms as specified in the description.

  式（II）的化合物是抗菌剂，其中Q代表以下式的基团：—N(OH)CH(═O)或以下式的基团：—C(═O)NH(OH)；R1代表氢、C1-C6烷基或被一个或多个卤素原子取代的C1-C6烷基，或者当Q不是以下式的基团：—N(OH)CH(═O)时，代表一个羟基、C1-C6烷氧基、C1-C4烯氧基、氨基、C1-C4烷基氨基或二-(C1-C6烷基)氨基；R2代表取代或未取代的C1-C6烷基、环烷基(C1-C6烷基)-或芳基(C1-C6烷基)-基团；A代表式（IIA）或（IIB）中的一个基团，其中R4代表天然或非天然α-氨基酸的侧链，当R5和R6与它们连接的氮原子一起形成描述中指定的由5到7个原子组成的饱和杂环第一环。
• Compounds as inhibitor of tumor necrosis factor alpha release
  申请人：Hoffmann-La Roche Inc.

  公开号：US06239151B1

  公开（公告）日：2001-05-29

  The invention provides hydrazine derivatives of the formula wherein R1 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R2 is an acyl group derived from an &agr;-, &bgr;-, &ggr;- or &dgr;-(amino, hydroxy or thiol)carboxylic acid in which the amino, hydroxy or thiol group is optionally lower alkylated or the amino group is optionally acylated, sulphonylated or amidated and in which any functional group present in a side-chain is optionally protected, or a group of the formula Het(CH2)mCO; R3 is hydrogen, lower alkyl, halo-lower alkyl, cyano-lower alkyl, amino-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, heterocyclyl-lower alkyl, heterocyclylcarbonyl-lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl-lower alkenyl, aryl or heterocyclyl; R4 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a grouping of the formula X-aryl, X-heteroaryl or —(CH2)n—CH═CR5R6; R5 and R6 together are lower alkylene in which one CH2 group is optionally replaced by a hetero atom; Het is heterocyclyl; X is a spacer group; m is 0, 1, 2, 3 or 4; and n is 1 or 2; and their pharmaceutically acceptable salts inhibit the release of tumour necrosis factor alpha (TNF-&agr;) from cells. They can be used as medicaments, especially in the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumours, cachexia, cardiovascular diseases, fever, haemorrhage and sepsis.

  该发明提供了以下结构的肼衍生物 其中R1是较低的烷基、较低的烯基、较低的环烷基、较低的环烷基-较低的烷基、芳基或芳基-较低的烷基；R2是从α-、β-、γ-或δ-(氨基、羟基或硫醇)羧酸衍生的酰基，其中氨基、羟基或硫醇基可选择性地被较低的烷基化，或氨基可选择性地被酰化、磺酰化或酰胺化，并且侧链中存在的任何官能团可选择性地被保护，或者是Het(CH2)mCO的结构；R3是氢、较低的烷基、卤代较低的烷基、氰基-较低的烷基、氨基-较低的烷基、羟基-较低的烷基、较低的烷氧基-较低的烷基、较低的烷氧羰基-较低的烷基、较低的环烷基-较低的烷基、芳基-较低的烷基、杂环烷基-较低的烷基、杂环烷基羰基-较低的烷基、较低的烯基、较低的炔基、较低的环烷基、芳基-较低的烯基、芳基或杂环烷基；R4是较低的烷基、较低的烯基、较低的环烷基、较低的环烷基-较低的烷基或X-芳基、X-杂环芳基或—(CH2)n—CH=CR5R6的结构；R5和R6一起是较低的烷基，其中一个CH2基可选择性地被杂原子取代；Het是杂环烷基；X是间隔基；m为0、1、2、3或4；n为1或2；它们的药学上可接受的盐抑制肿瘤坏死因子α(TNF-α)从细胞中释放。它们可用作药物，特别是用于治疗炎症和自身免疫性疾病、骨关节炎、呼吸道疾病、肿瘤、消瘦症、心血管疾病、发热、出血和败血症。